News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website


Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35840

Posted on: 10/04/2008

Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.

Sub-category:

Central Nervous System Tumors

Category:

Central Nervous System Tumors

Meeting:

2008 ASCO Annual Meeting

 Printer Friendly

 E-Mail Article

Abstract No:

2011

Citation:

J Clin Oncol 26: 2008 (May 20 suppl; abstr 2011)

Author(s):

J. H. Sampson, G. E. Archer, D. D. Bigner, T. Davis, H. S. Friedman, T. Keler, D. A. Mitchell, D. A. Reardon, R. Sawaya, A. B. Heimberger

Abstract:

Background: Conventional therapies for GBM fail to target tumor cells exclusively. Immunologic targeting of tumor- specific gene mutations may allow more precise eradication of neoplastic cells. The epidermal growth factor receptor variant III (EGFRvIII) is a consistent and immunogenic mutation that is not expressed in any normal tissues, but is widely expressed in GBMs and other neoplasms making it an attractive target for active immunotherapy. Methods: A phase II multicenter clinical trial was undertaken to assess the immunogenicity and efficacy of an EGFRvIII-specific peptide vaccine in patients with newly-diagnosed, EGFRvIII+ GBM in combination with simultaneous standard or continuous temozolomide (TMZ). After resection and radiation/TMZ (75 mg/m2/d), consecutive cohorts received subsequent monthly cycles of 200 mg/m2 (N=13) or continuous 100 mg/m2 (N=8) TMZ simultaneous with intradermal vaccinations with an EGFRvIII-specific peptide (PEPvIII) conjugated to keyhole limpet hemocyanin (KLH) until tumor progression or death. Results: 21 patients were enrolled. There was one allergic reaction, but no other SAEs. There were no significant differences in vaccine immunogenicity (p>0.999; binomial proportions), PFS (p=0.7979; log-rank), or OS (p=0.7728; log-rank) between TMZ regimens. Although TMZ induced grade II lymphopenia in 53.8% of patients, the co-administration of TMZ with the EGFRvIII vaccine (CDX-110) results in strong sustained immune responses to EGFRvIII in 100% (95%CI: 0.72, 1.00) of evaluated patients. Median PFS was 16.6 months (95%CI: 9.1, 22.7). Median survival has not been reached. The survival of the vaccinated patients is better than a matched historical control group (14.3 months; 95%CI: 13.0, 16.2) (p<0.0001; log-rank) and a subgroup treated with TMZ (15.2; 95%CI: 13.9, 20.5) (p=0.0078) and is also equivalent to the results seen in patients vaccinated without simultaneous temozolomide (p=0.4108; log-rank). Conclusions: CDX-110 peptide vaccination with standard of care temozolomide in patients with GBM appears very promising and is under investigation in a phase III, randomized clinical trial.

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740